

## Cancer Associated Cachexia; Etiopathogenesis, Molecular Mechanisms and Therapeutic Strategies

Mohamed Hassan<sup>1,2,3\*</sup>, Abdelouahid El-khattouti<sup>1</sup>, Youssef Haikel<sup>2,3</sup> and Mossaad Megahed<sup>4</sup>

<sup>1</sup>Cancer Institute, University of Mississippi Medical Center, Jackson, MS 39216, USA

<sup>2</sup>Institut National de la Santé et de la Recherche Médicale, U1121, France

<sup>3</sup>Department of Operative Dentistry and Endodontics, Dental Faculty, University of Strasbourg, 67000 Strasbourg, France

<sup>4</sup>Clinic of Dermatology, University Hospital of Aachen, Pauwelsstr. 30, 52074 Aachen, Germany

\*Corresponding author: Mohamed Hassan, Cancer Institute, University of Mississippi, Medical Center, Jackson, MS, USA, Tel.: +1 601 815 8945; Fax: +1 601 984 29 81; E-mail: dr.hassan@gmx.de

Rec date: Jul 10, 2014, Acc date: Aug 21, 2014, Pub date: Aug 23, 2014

Copyright: © 2014 Hassan M, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

### Abstract

Cachexia is a multifunctional syndrome that is characterized by anorexia and extensive loss of adipose tissue and skeletal muscle, is common in many chronic and advanced diseases. Most of cancer patients show variable patterns of body loss that is known as cancer associated cachexia (CAC). Although CAC share common characteristics, the severity of this disease is variable, and seems to be tumor type, site and stage-dependent. The etiology of cachexia is attributed to abnormal metabolism that is thought to be mediated by tumor- and host-derived cytokines and factors. Although the role of cytokines in the etiology of CAC has been reported, the molecular mechanisms regulating its occurrence in cancer patients are not described in details. This review focuses on the etiopathogenesis of CAC and the underlying mechanisms.

### Introduction

Cachexia is a multifunctional syndrome that is common in many chronic and advanced diseases including cancer [1]. Accordingly, most cancer patients show variable patterns of cachexia that is known as cancer associated cachexia (CAC) [2]. The severity of CAC is variable and seems to be tumor type, site and stage-dependent [3]. Of note, CAC is significantly marked in patients suffering from gastrointestinal and pancreatic adenocarcinoma [4,5], with lesser extent in patients suffering from other carcinomas such as acute leukemia, malignant lymphoma and sarcoma [6]. The release of cachexia depends strongly on host susceptibility to respond to tumor development and progression via mechanism mediated by the activation of immune system and its associated pathways [7]. As widely reported CAC is associated with physical impairment that is attributed to the loss of body weight, white adipose tissues and skeletal muscle mass [8]. Accordingly, these disastrous conditions are estimated to cause death in cancer patients [9]. Although progressive studies have been made to understand the etiopathogenesis of cachexia syndrome, an effective therapy to cure or to prevent cancer cachexia is not inspection. The development of an efficient therapy for cachexia treatment is hampered by the fact that the cachexia syndrome is not exactly defined, diagnostic criteria are absent, and the mechanisms underlying CAC are not determined in detail. In this review, we provide insight into the etiopathogenesis of CAC, the molecular mechanisms, which are essential for the occurrence of CAC and its therapy.

### Etiopathogenesis of Cancer Associated Cachexia

Cachexia as known is a complex syndrome that is associated with body weight loss, tissue wasting, systemic inflammation, metabolic abnormalities [10]. The etiology of CAC is attributed to abnormal metabolism, particularly, catabolism, as a response to cancer-induced

anorexia, aggressive therapeutic regimens-induced malabsorption, and excessive release of tumor and host-derived cytokines and factors [11-14]. Also, inflammatory cytokines are thought to play a fundamental role in the pathogenesis of cachexia via mechanism mediated by the activation of ubiquitin-proteasome pathway [15]. Of note, the most noticeable features of cachexia is the loss of muscle mass that may result from the increased protein degradation rates via excessive activation ubiquitin-proteasome pathway [16,17].

Although host and tumor cytokines and factors, which are thought to be implicated in the regulation of CAC have been identified, the mechanism whereby tumors cause cachexia is not completely characterized in detail [11-14]. The induction of cachexia is a stochastic process that may result from random mutations occurring in the tumor. Other plausible explanation for the occurrence of cachexia in cancer patients may result from host response to the molecular action of antitumor drugs that are mostly associated with the inflammatory reactions leading to the release of various cytokines. Apart from anticancer agents-induced cachexia, the induction of cachexia in tumor patients seems to be a tumor strategy to maintain its high energy requirements that are needed for tumor growth and progression. However, the appearance of CAC is associated with the release of energy sources such as glucose, lactate, and fatty acid from white adipose tissue, and amino acids from protein degradation of skeletal muscle mass [18]. Accordingly, in vivo experiments demonstrated that the dietary supplements significantly affect tumor growth [19], an evidence for the important role of metabolic alteration in the regulation of cachexia in tumor patients. Also, the importance of circulating fatty acids for tumor growth has been reported in tumor models of acute fasting or streptozotocin-induced diabetes [20,21]. Although some rapidly proliferating tumors are mostly associated with suver cachexia, severe cachexia has been reported in patients with small tumor burden and low proliferation rate [22]. Thus, it seems that

the variation of the genetic changes in tumors results in significant alterations of tumor metabolism that, in turn, mediate pathways leading to the induction of CAC in response to excessive release of tumor- and host-derived cytokines, cancer-induced anorexia and aggressive therapeutic regimens (Figure 1).




Figure 1: Etiopathogenesis of cancer associated cachexia.

### Molecular Mechanisms of Cancer-mediated Cachexia

The induction of cachexia during the course of tumor malignancy is caused by complex metabolic disorders. Although the basal metabolism in cancer patients with malignant diseases significantly elevated [23], and results from the reduction of the voluntary energy expenditure that is manifested clinically as fatigue, apathy, and depression [24], not from the restricted intake and alterations in the mechanisms that are associated with the usual fasting-feeding conditions. Also, the increase of lipolysis, along with the decrease of lipogenesis, enhances the loss of white adipose tissue and subsequently leads to a rapid decrease of the lipoprotein lipase activity in the white adipose [25,26]. As a consequence, the levels of the circulating triglycerides and lipase maturation factor 1 (LMF-1) increase leading to the loss of body fat and, in turn, increases lipid metabolism in cancer patients [27]. In solid tumors the production of lactate is in excess and its conversion to glucose occurs in the liver by the Cori cycle, a mechanism that leads to the increase of the production of hepatic glucose. Thus, the appearance of glucose intolerance in most of tumor patients may be the consequence of the increased hepatic production of glucose and restricted insulin production [28,29]. The mechanism whereby the loss of skeletal muscle mass is thought to result from the circulation of the proteolysis inducing factor (PIF) in the blood. This PIF has the ability to induce proteolysis and subsequently inhibiting protein synthesis [30,31]. Also, PIF can mediate the activation of the ubiquitin-proteasome pathway that is considered to be the principal mediator of the catabolism of cellular protein [30]. Of note, the main mechanism whereby PIF induces catabolism in skeletal muscle is mediated the up-regulation of the ATP-ubiquitin-dependent proteolytic pathway [31,32].

Although the reduction of food intake influences the energy expenditure, the imbalance between pro-inflammatory and anti-inflammatory is essential for the development of CAC [4,33]. The role

of cytokines such as, tumor necrosis factor-alpha (TNF-α), interferon-gamma (IFN-γ), interleukins-1(IL-1) and interleukins-6 (IL-6) in the modulation of CAC has been reported [33]. Also, cytokines such as vascular endothelial growth factors A and C (VEGF-A and VEGF-C) and interleukin-8 (IL-8) have been shown to be involved indirect role the modulation of CAC via a mechanism mediated by the recruitment and degranulation of inflammatory cells. However, the recruitment and degranulation of inflammatory cells result in the stimulation of other pro-inflammatory agents that finally lead to the remodeling and degradation of extracellular matrix [34]. More importantly, the induction of these pro-inflammatory cytokines is regulated by pro-cachectic factors such as PIF via mechanism mediated by the transcription factors NF-κB and/or AP-1 [35-38]. The molecular mechanism whereby cancer triggers cachexia is outlined in Figure 2.




Figure 2: Molecular mechanism responsible for the loss of adipose tissue and skeletal muscle during cancer associated cachexia. The production of cancer associated factors and cytokines e.g. lipid-mobilizing factor (LMF), tumor necrosis factor (TNF)-α and proteolysis-inducing factor (PIF). The increased levels of TNF-α and LMF in tumor patients results in the hydrolysis of triglycerides in adipose tissues through the breakdown of cyclic AMP (cAMP) that, in turn, reduces the activation of hormone-sensitive lipase (HSL). Also, high level of TNF-α can suppress the peroxisome proliferator-activated receptor γ (PPARγ) and subsequently inhibits the biosynthesis of TG. Once TNF-α-induced free fatty acids (FFAs) enter the liver, the β-oxidation of FAA produces energy in the form of adenine triphosphate (ATP) in addition to the production CO<sub>2</sub>. ATP drives the cori cycle to convert lactate, glycerol, amino acids to glucose. The induction of proteolysis inducing factor (PIF) increases the production of proteasome subunits and thereby enhances protein degradation in skeletal muscle.

### Therapeutic Strategies for Cancer Associated Cachexia

The continuous preclinical studies with the aim to identify the potential molecular targets for the treatment of muscle wasting, addressed a crucial role for the involvement of ubiquitin ligases in pathological muscle degradation. Although increased muscle protein degradation is the main mechanism underlying muscle wasting in

cancer, it is uncertain whether the destruction of ubiquitin-proteasome pathway reverse CAC. However, the most effective therapeutic strategy for the treatment or prevention of CAC is the eradication of cancer with surgical and/or nonsurgical therapy.

The available therapeutic strategies for CAC treatment are either pharmacological or nutritional approaches. However, the ideal therapeutic approach for the treatment of CAC is with drug compound that acquires the ability to increase food intake, prevent muscle loss and improve muscle weight. Unfortunately, accumulated evidence revealed that nutritional strategies are insufficient to reverse CAC [38]. Thus, the development of therapeutic strategies based on the combination of both nutritional and pharmacological approaches may only be able to prevent cachectic syndrome. Thus, the nutritional therapeutic might help to increase food intake, whereas the pharmacological approaches might counteract the metabolic alterations. Because of the mediators of CAC are not completely investigated the design of an efficient therapeutic protocol for the prevention or treatment of cachectic syndrome is complicated.

Both tumor- and host-derived factors, mainly cytokines are involved in the modulation of cachexia and thereby are considered a great obstacle for the development of an efficient drug or even the design of a management therapeutic protocol for the treatment of cachectic syndrome.

Currently, megestrol acetate (MA) and medroxyprogesterone are the most used drugs for the treatment of CAC. These compounds can improve appetite, caloric intake and nutritional status as shown in several clinical trials [38,39]. Compounds, such as MA are well tolerated in patients with advanced cancer and have been found to improve body weight and sense of appetite, particularly, in patients with tumors underlying resistance to hormonal treatments [40,41]. Also, data obtained from several clinical studies revealed that MA is thought to be one of the most investigated appetite stimulants of the available therapeutic approaches of cachexia [42,43]. Moreover, accumulated evidences indicate that both MA and medroxyprogesterone acetate treatment are able to improve the quality of the life of cancer patients underlying chemo-and/or radiotherapy [44-47]. Interestingly, the therapeutic action of the MA is not only limited to the improvement of the appetite and subsequently the body weight, but also ameliorate muscle mass and performance via mechanism mediated by the inhibition of protein degradation machinery [48].

Although the therapeutic efficiency of MA promising, the molecular mechanisms regulating its therapeutic action in cachexia syndrome are not discussed in detail.

In addition to its effect on appetite, MA has been reported to increase the levels of neuropeptide Y and to enhance the inhibition of Ca<sup>2+</sup> channel current, leading to the reduction of the activity of the ventromedial hypothalamic nucleus neurons mediating the satiety mechanism [49]. Also, MA can influence the molecular mechanisms regulation of both metabolic and inflammatory processes [50]. Accordingly, *in vitro* analysis demonstrated the ability of suppress the production of both serotonin and cytokines including interleukin-1b (IL-1), interleukin-6 (IL-6) and tumor necrosis factor- $\alpha$  (TNF $\alpha$ ), host-derived factors that function as mediators for the development of cachexia during the course of malignancy [51]. Furthermore, the treatment with MA has been found to increase the level of the circulating IL-15, a cytokine that functions as an anabolic factor for skeletal muscle [52]. Of note the alterations of cytokines

concentration, in response to the treatment, do not influence muscle mass, but rather increases fat mass [52]. This may result from the increase in food intake and the effect of the progestagen on the differentiation of adipocytes [53].

The mechanism whereby MA inhibit protein degradation and subsequently the loss of muscle mass, an evidence for MA to function as an anti-proteolytic agent is mediated by the suppression of the ubiquitin, E2 and atrogin-1 levels in muscles [54]. This noted anti-proteolytic function of MA thought to be based on an inhibition of the ATP-ubiquitin dependent proteolytic mechanism. Accordingly, the ubiquitin proteasome pathway is considered as a promising therapeutic target for CAC.

## Conclusion

Cachexia is a complex syndrome that is associated with body weight loss, tissue wasting, systemic inflammation, metabolic abnormalities, in addition to alterations in nutritional status. Accumulated experimental and clinical reports demonstrate that cancer associated cachexia results from fundamental metabolic alterations as a consequence of the accumulation of host- and tumor derived cytokines and factors. Thus, underlying metabolic disturbances are thought to occur in the early stage of tumor development without any sign for weight loss, as a marker for cachexia. The occurrence of cachexia is not attributed solely to the decrease of food intake or to tumor/host; it results from extremely metabolic alterations in tissues in response tumor catabolic factors. The enhancement of these tumor catabolic factors is mediated by pro-inflammatory cytokines and cellular factors derived from host and tumor tissues. These cytokines and cellular factors are thought to be the host mediators leading to the destruction and/or excessive activation of variable signaling pathways that ultimately mediates cachectic syndrome in cancer patients. Thus, understanding the fundamental mechanisms of the cachectic syndrome in cancer patients will help to design a therapeutic strategy for the treatment CAC and to improve the quality life of cancer patients.

## References

1. Mastrocola R, Reffo P, Penna F, Tomasinelli CE, Boccuzzi G, et al. (2008) Muscle wasting in diabetic and in tumor-bearing rats: role of oxidative stress. *Free Radic Biol Med* 44: 584-593.
2. Johns N, Hatakeyama S, Stephens NA, Degen M, Degen S, et al. (2014) Clinical classification of cancer cachexia: phenotypic correlates in human skeletal muscle. *PLoS One* 9: e83618.
3. Blum D, Omlin A, Baracos VE, Solheim TS, Tan BH et al. (2011) Cancer cachexia: a systematic literature review of items and domains associated with involuntary weight loss in cancer. *Crit Rev Oncol Hematol* 80: 114-144.
4. Diakowska D, Krzystek-Korpacka M, Markocka-Maczka K, Diakowski W, Matusiewicz M, et al. (2010) Circulating leptin and inflammatory response in esophageal cancer, esophageal cancer-related cachexia-anorexia syndrome (CAS) and non-malignant CAS of the alimentary tract. *Cytokine* 51: 132-137.
5. Bachmann J, Heiligensetzer M, Krakowski-Roosen H, Buchler MW, H. Friess, et al. (2008) Cachexia worsens prognosis in patients with resectable pancreatic cancer. *J Gastrointest Surg*: 12: 1193-1201.
6. Tsujimoto S, Kawamura I, Inami M, Lacey E, Nishigaki F, et al. (2000) Cachexia induction by EL-4 lymphoma in mice and possible involvement of impaired lipoprotein lipase activity. *Anticancer Res* 20: 3111-3116.

7. Kumar S, Kishimoto H, Chua HL, Badve S, Miller KD, et al. (2003) Interleukin-1 alpha promotes tumor growth and cachexia in MCF-7 xenograft model of breast cancer. *Am J Pathol* 163: 2531-2541.
8. Op den Kamp CM, Langen RC, Minnaard R, Kelders MC, Snepvangers FJ, et al. (2012) Pre-cachexia in patients with stages I-III non-small cell lung cancer: systemic inflammation and functional impairment without activation of skeletal muscle ubiquitin proteasome system. *Lung cancer* 76: 112-117.
9. Rydén M, Agustsson T, Laurencikiene J, Britton T, Sjölin E, et al. (2008) Lipolysis--not inflammation, cell death, or lipogenesis--is involved in adipose tissue loss in cancer cachexia. *Cancer* 113: 1695-1704.
10. Vaughan VC, Martin P, Lewandowski PA (2013) Cancer cachexia: impact, mechanisms and emerging treatments. *J Cachexia Sarcopenia Muscle* 4: 95-109.
11. Chiba F, Soda K, Yamada S, Tokutake Y, Chohnan S, et al. (2014) The importance of tissue environment surrounding the tumor on the development of cancer cachexia. *Int J Oncol* 44: 177-186.
12. Zastrow A, Wolf J, Giannitsis E, Katus H, Herzog W, et al. (2011) Elevated myocardial enzymes and natriuretic peptides in anorexia nervosa: prototypic condition for the pathophysiology of cachexia? *Cardiology* 118: 256-259.
13. Smiechowska J, Utech A, Taffet G, Hayes T, Marcelli M, et al. (2010) Adipokines in patients with cancer anorexia and cachexia. *Journal of investigative medicine. Journal of Investigative Medicine* 58: 554-559.
14. Kohlschütter B, Jehn U (1978) Parenteral feeding during aggressive chemotherapy of various neoplasms. *Onkologie* 1: 31-34.
15. Strickson S, Campbell DG, Emmerich CH, Knebel A, Plater L, et al. (2013) The anti-inflammatory drug BAY 11-7082 suppresses the MyD88-dependent signalling network by targeting the ubiquitin system. *Biochem J* 451: 427-437.
16. Lokireddy S, Wijesoma IW, Teng S, Bonala S, Gluckman PD, et al. (2012) The ubiquitin ligase Mull1 induces mitophagy in skeletal muscle in response to muscle-wasting stimuli. *Cell Metab* 16: 613-624.
17. Couch ME, Dittus K, Toth MJ, Willis MS, Guttridge DC, et al. (2014) Cancer cachexia update in head and neck cancer: Definitions and diagnostic features. *Head & neck [In Press]*.
18. Szabó T, Postrach E, Mähler A, Kung T, Turhan G, et al. (2013) Increased catabolic activity in adipose tissue of patients with chronic heart failure. *Eur J Heart Fail* 15: 1131-1137.
19. Uster A, Ruefenacht U, Ruehlin M, Pless M, Siano M, et al. (2013) Influence of a nutritional intervention on dietary intake and quality of life in cancer patients: a randomized controlled trial. *Nutrition* 29: 1342-1349.
20. Nuutinen J, Minn H, Bergman J, Haaparanta M, Ruotasalainen U, et al. (1999) Uncoupling of fatty acid and glucose metabolism in malignant lymphoma: a PET study. *Br J Cancer* 80: 513-518.
21. Sauer LA, Dauchy RT (1987) Stimulation of tumor growth in adult rats in vivo during acute streptozotocin-induced diabetes. *Cancer Res* 47: 1756-1761.
22. McAndrew PG, Nicholl AD, Beck PR, Edbrooke DL (1982) The syndrome of inappropriate antidiuretic hormone secretion. *Br J Oral Surg* 20: 256-259.
23. PetrÅk O, HaluzÅkovÅ; D, KavÅ;lkovÅ; P, Å trauch B, Rosa J, et al. (2013) Changes in energy metabolism in pheochromocytoma. *J Clin Endocrinol Metab* 98: 1651-1658.
24. Shatnawei A, Hamilton C, Quintini C, Steiger E, Kirby DF (2010) Use of home parenteral nutrition in patients with intra-abdominal desmoid tumors. *Nutrition in clinical practice* 25: 290-295.
25. Xiong Y, Qu Z, Chen N, Gong H, Song M, et al. (2014) The local corticotropin-releasing hormone receptor 2 signalling pathway partly mediates hypoxia-induced increases in lipolysis via the cAMP-protein kinase A signalling pathway in white adipose tissue. *Mol Cell Endocrinol* 392: 106-114.
26. Pinent M, Prokesch A, Hackl H, Voshol PJ, Klatzer A, et al. (2011) Adipose triglyceride lipase and hormone-sensitive lipase are involved in fat loss in JunB-deficient mice. *Endocrinology* 152: 2678-2689.
27. Cefalù AB, Noto D, Arpi ML, Yin F, Spina R, et al. (2009) Novel LMF1 nonsense mutation in a patient with severe hypertriglyceridemia. *J Clin Endocrinol Metab* 94: 4584-4590.
28. Facciorusso A, Barone M (2014) Glucose intolerance and hepatocellular carcinoma: recent findings for old diseases. *Hepatobiliary Surg Nutr* 3: 91-92.
29. Aggarwal G, Ramachandran V, Javeed N, Arumugam T, Dutta S, et al. (2012) Adrenomedullin is up-regulated in patients with pancreatic cancer and causes insulin resistance in  $\beta^2$  cells and mice. *Gastroenterology* 143: 1510-1517.
30. Mirza KA, Wyke SM, Tisdale MJ (2011) Attenuation of muscle atrophy by an N-terminal peptide of the receptor for proteolysis-inducing factor (PIF). *Br J Cancer* 105: 83-88.
31. Wyke SM, Tisdale MJ (2005) NF-kappaB mediates proteolysis-inducing factor induced protein degradation and expression of the ubiquitin-proteasome system in skeletal muscle. *Br J Cancer* 92: 711-721.
32. Lorite MJ, Thompson MG, Drake JL, Carling G, Tisdale MJ (1998) Mechanism of muscle protein degradation induced by a cancer cachectic factor. *Br J Cancer* 78: 850-856.
33. Krzystek-Korpacka M, Matusiewicz M, Diakowska D, Grabowski K, Blachut K, et al. (2007) Impact of weight loss on circulating IL-1, IL-6, IL-8, TNF-alpha, VEGF-A, VEGF-C and midkine in gastroesophageal cancer patients. *Clin Biochem* 40: 1353-1360.
34. Hardie WD, Korfhagen TR, Sartor MA, Prestridge A, Medvedovic M, et al. (2007) Genomic profile of matrix and vasculature remodeling in TGF-alpha induced pulmonary fibrosis. *Am J Respir Cell Mol Biol* 37: 309-321.
35. Moore-Carrasco R, Busquets S, Almendro V, Palanki M, Lopez-Soriano FJ, et al. (2007) The AP-1/NF-kappaB double inhibitor SP100030 can revert muscle wasting during experimental cancer cachexia. *Int J Oncol* 30: 1239-1245.
36. Moore-Carrasco R, Garcia-Martinez C, Busquets S, Ametller E, Barreiro E, et al. (2006) The AP-1/CJUN signaling cascade is involved in muscle differentiation: implications in muscle wasting during cancer cachexia. *FEBS Lett* 580: 691-696.
37. Watchorn TM, Dowidar N, Dejong CH, Waddell ID, Garden OJ, et al. (2005) The cachectic mediator proteolysis inducing factor activates NF-kappaB and STAT3 in human Kupffer cells and monocytes. *Int J Oncol* 27: 1105-1111.
38. Watchorn TM, Waddell I, Dowidar N, Ross JA (2001) Proteolysis-inducing factor regulates hepatic gene expression via the transcription factors NF-(kappa)B and STAT3. *FASEB J* 15: 562-564.
39. Mantovani G, Macciò A, Madeddu C, Serpe R, Massa E, et al. (2010) Randomized phase III clinical trial of five different arms of treatment in 332 patients with cancer cachexia. *Oncologist* 15: 200-211.
40. Greig CA, Johns N, Gray C, MacDonald A, Stephens NA, et al. (2014) Phase I/II trial of formoterol fumarate combined with megestrol acetate in cachectic patients with advanced malignancy. *Support Care Cancer* 22: 1269-1275.
41. Penel N, Clisant S, Dansin E, Desauw C, Degardin M, et al. (2010) Megestrol acetate versus metronomic cyclophosphamide in patients having exhausted all effective therapies under standard care. *Br J Cancer* 102: 1207-1212.
42. Golebiewska JE, Lichodziejewska-Niemierko M, Aleksandrowicz-Wrona E, Majkovic M, Lysiak-Szydłowska W, et al. (2012) Influence of megestrol acetate on nutrition, inflammation and quality of life in dialysis patients. *Int Urol Nephrol* 44: 1211-1222.
43. Herrejon A, Palop J, Inchaurrega I, Lopez A, Banuls C, et al. (2011) Low doses of megestrol acetate increase weight and improve nutrition status in patients with severe chronic obstructive pulmonary disease and weight loss. *Med Clin (Barc)* 137: 193-198.
44. Bevis KS, Kilgore LC, Alvarez RD, Straughn JM Jr, Leath CA 3rd (2014) Combination therapy with paclitaxel, carboplatin and megestrol acetate

- for the management of advanced stage or recurrent carcinoma of the endometrium: a phase II study. *J Reprod Med* 59: 113-120.
45. Zaucha R, Sosińska Mielcarek K, Jassem J (2004) Long-term survival of a patient with primarily chemo-resistant metastatic breast cancer treated with medroxyprogesterone acetate. *Breast* 13: 321-324.
46. McQuellon RP, Moose DB, Russell GB, Case LD, Greven K, et al. (2002) Supportive use of megestrol acetate (Megace) with head/neck and lung cancer patients receiving radiation therapy. *Int J Radiat Oncol Biol Phys* 52: 1180-1185.
47. Lhommé C, Brault P, Bourhis JH, Pautier P, Dohollou N, et al. (2001) Prevention of menstruation with leuprorelin (GnRH agonist) in women undergoing myelosuppressive chemotherapy or radiochemotherapy for hematological malignancies: a pilot study. *Leuk Lymphoma* 42: 1033-1041.
48. Busquets S, Serpe R, Sirisi S, Toledo M, Coutinho J, et al. (2010) Megestrol acetate: its impact on muscle protein metabolism supports its use in cancer cachexia. *Clin Nutr* 29: 733-737.
49. Costa AM, Spence KT, Plata-Salaman CR, French-Mullen JM (1995) Residual Ca<sup>2+</sup> channel current modulation by megestrol acetate via a G-protein alpha s-subunit in rat hypothalamic neurones. *J Physiol* 487: 291-303.
50. Ronga I, Gallucci F, Riccardi F, Uomo G (2014) Anorexia-cachexia syndrome in pancreatic cancer: recent advances and new pharmacological approach. *Adv Med Sci* 59: 1-6.
51. Jatoi A, Egner J, Loprinzi CL, Sloan JA, Novotny PJ, et al. (2004) Investigating the utility of serum cytokine measurements in a multi-institutional cancer anorexia/weight loss trial. *Support Care* 12: 640-644.
52. Lambert CP, Flynn MG, Sullivan DH, Evans WJ (2004) Effects of megestrol acetate on circulating interleukin-15 and interleukin-18 concentrations in healthy elderly men. *J Gerontol A Biol Sci Med Sci* 59: 855-858.
53. Lacasa D, Le Liepvre X, Ferre P, Dugail I (2001) Progesterone stimulates adipocyte determination and differentiation 1/sterol regulatory element-binding protein 1c gene expression. potential mechanism for the lipogenic effect of progesterone in adipose tissue. *J Biol Chem* 276: 11512-11516.
54. Gullett N, Rossi P, Kucuk O, Johnstone PA (2009) Cancer-induced cachexia: a guide for the oncologist. *J Soc Integr Oncol* 7: 155-169.